DiabetesDIABESTNCT05488210
Study About Adherence and Tolerance of an Oral Nutritional Supplement (ONS) Specific for Diabetic Patient.
An observational study of Diabetes and Malnutrition, run by Instituto de Investigación Hospital Universitario La Paz at 1 site in Spain.
Trial summary
Diabetes Mellitus (DM) is one of the most prevalent chronic diseases today, it is reaching epidemic proportions, mainly caused by the increase in type 2 diabetes (DM2).The foundation of any hypoglycemic treatment is based on a healthy diet, daily physical exercise and adequate health education with the collaboration… Read more about this study
- Who is it for?
- Ages 18 to 85 yearsHealthy volunteers can take part
- Conditions the study is for
- Diabetes, Malnutrition
- What is being tested?
- FontActiv DiaBest HP/HC
- How many people
- 24 participants
- Where
- 1 siteSpain
- Study dates
- 1 Jul 2022to 1 Jul 2023
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 85 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: Diabetic patients who present malnutrition through the GLIM criteria
Who may be able to join
- Men and women enter 18 and 85 years old.
- Patients with DM2 previously diagnosed and controlled.
- Patients with malnutrition diagnosed according to GLIM criteria.
- Patients who require taking ONS.
- Patients willing to consume the ONS during the study period.
- Patients with adequate cultural level and understanding of the clinical study.
- Patients who agree to voluntarily participate in the study and who give their informed consent in writing.
Who cannot join
- Subjects with enteral or parenteral nutrition.
- Subjects with poorly controlled DM2.
- Subjects with dementia, eating behavior disorders, history of serious neurological or psychiatric pathology that may interfere with adherence to the consumption of the ONS.
- Subjects suffering from alcoholism or substance abuse that may interfere with adherence to the consumption of the ONS.
- Subjects with a diagnosis of kidney or liver disease under pharmacological treatment.
- Subjects with infections or any condition that interferes with nutrient digestion, absorption, metabolism, or excretion (including gastroparesis).
Show all 10Show fewer
- Subjects with chronic gastrointestinal diseases that affect the digestion or absorption of nutrients.
- Subjects with allergies or intolerances to any of the ingredients of the formula.
- Subjects with socio-family problems that prevent them from participating in the study.
- Pregnant or lactating women.
Trial locations and contacts
1 site in 1 country.
Spain1 site, 1 recruiting
- Recruiting
Samara Palma Milla
Madrid, 28046
Samara Palma Milla, PhD, 917277000 ext. 441209, samara.palma@salud.madrid.org
samara.palma@salud.madrid.org
About this study
Official title: Study to Evaluate the Effect of Consuming an Oral Nutritional Supplement (ONS) Specifically for Diabetic Patients on Adherence and Gastrointestinal Tolerance and Nutritional Status in Patients With DM2 and Malnutrition
Diabetes Mellitus (DM) is one of the most prevalent chronic diseases today, it is reaching epidemic proportions, mainly caused by the increase in type 2 diabetes (DM2).The foundation of any hypoglycemic treatment is based on a healthy diet, daily physical exercise and adequate health education with the collaboration of the patient. Diet is sometimes the only necessary therapy since approximately 80% of patients with DM2 are usually overweight, what is mainly wanted with diet is to achieve normal blood glucose levels both fasting and in the postprandial phase. This diet must be a varied diet combining foods from the different food groups; however, carbohydrate control must be one of the key strategies for glycemic control. Currently, there is also talk of the concept of disease-related malnutrition (DRM). DRM is malnutrition associated with a pathological state, with the presence of inflammation being a key factor in determining its etiology. This inflammation can be chronic or acute depending on the type of pathology. Therefore, the fiber and carbohydrate composition of oral nutritional supplements are important for glycemic control, so a study is proposed to evaluate the effect of consuming a ONS hypercaloric/high-protein (HC/HP) with fiber, and enriched in calcium, Vitamin D and DHA on adherence and tolerance of the product and nutritional status in patients with DM2 and malnutrition.
Read the detailed description
Longitudinal, prospective exploratory study, to evaluate the effect of consuming an oral nutritional supplement (ONS) HC/HP with fiber, and enriched in calcium, Vitamin D and Docosahexaenoic acid (DHA) on adherence and tolerance of the product and nutritional status in patients with DM2 and malnutrition, in a period of 60 days. Twenty-four volunteers will be recruited at the La Paz University Hospital of Madrid. Participants should meet the next inclusion criteria: men and woman enter 18 and 85, with DM2 previously diagnosed and controlled, with malnutrition diagnosed according to the Global Leadership Initiative on Malnutrition (GLIM) criteria, who require taking ONS, willing to consume the ONS during the study and adequate cultural level and understanding of the clinical study. Follow up will include 4 individualized visits.
- Conditions
- Diabetes, Malnutrition
- Being tested
- FontActiv DiaBest HP/HC
- Keywords
- DM2, Oral nutritional supplement, Malnourished
- Medical subject headings
- Diabetes Mellitus, Malnutrition
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
FontActiv DiaBest HP/HCDietary supplement
Also called Experimental
Daily intake of two FontActiv DiaBest HP/HC during 2 months
| Study group | Role | What they receive |
|---|---|---|
| Malnourished DM2 patients | Diabetic patients who present malnutrition through the GLIM criteria Receives: Dietary Supplement: FontActiv DiaBest HP/HC |
What is being measured
The primary outcome is the main question the study is designed to answer.
Weight gain (kg)
Changes in body weight. It is measured using a digital scale for clinical use (capacity 0-150 kg),with the person positioned with their back to the viewer, without shoes, wearing a minimum of warm clothing (pants and t-shirt), heels together, looking forward and posture straight body.
Measured: Day 0, Day 60
Fat mass (%)
Changes in the percentage (%) of Fat Mass via bioelectrical impedance
Measured: Day 0, Day 60
Muscle mass (%)
Changes in the percentage (%) of Muscle Mass via bioelectrical impedance
Measured: Day 0, Day 60
Secondary outcomes (24)
Waist circumference (cm)
The subject assumes a position with arms crossed at the chest. The perimeter is taken at the narrowest level, between the lower costal margin (10th rib) and the iliac crest. The anthropometrist stands in front of the subject, who has his arms slightly abducted, to allow the waist to run around the abdomen. Values greater than 80 centimeters (women) and 94 centimeters (men) are considered a risk for cardiovascular diseases.
Measured: Day 0, Day 60
Body Mass Index (kg/m2)
It is the relationship between the individual's body weight (kg) and height (m) squared: Weight/Height2. Values greater than 24,9 kg/m2 are considered as overweight
Measured: Day 0, Day 60
Extracellular water (%)
Changes in the percentage (%) of Extracellular Water via bioelectrical impedance
Measured: Day 0, Day 60
Intracellular water (%)
Changes in the percentage (%) of Intracellular Water via bioelectrical impedance
Measured: Day 0, Day 60
Total Body Water (%)
Changes in the percentage (%) of Total Body Water via bioelectrical impedance
Measured: Day 0, Day 60
Phase angle (º)
Changes in the phase angle (grades) via bioelectrical impedance
Measured: Day 0, Day 60
Body Cell Mass (%)
Changes in the percentage (%) of Body Cell Mass via bioelectrical impedance
Measured: Day 0, Day 60
Albumin serum concentration (g/dL)
Changes in serum albumin concentration. The normal range is 3.4 to 5.4 g/dL (34 to 54 g/L)
Measured: Day 0, Day 60
Prealbumin serum concentration (mg/dL)
Changes in serum prealbumin concentration. Normal results in adults range between 15 and 36 milligrams per deciliter (mg/dL) or 150 and 360 milligrams per liter (mg/L)
Measured: Day 0, Day 60
Glucose serum concentration (mg/dL)
Changes in fasting serum glucose concentration. The levels are between 74 and 100 mg/dL.
Measured: Day 0, Day 60
Insulin serum concentration (IU/mL)
Changes in serum insulin levels. A basal insulin level between 5-25 IU/ml is considered normal, higher than 30 U/ml suggests insulin resistance. Insulin maximum value 6 to 8 times the basal value.
Measured: Day 0, Day 60
HbA1c serum concentration (%)
Changes in the percentage of HbA1c. An HBA1c level of less than 5.7% is normal, 5.7 to 6.4% indicates prediabetes, and 6.5 or greater indicates diabetes. Within the prediabetes range (5.7 to 6.4%), the higher the A1c value, the greater the risk of developing type 2 diabetes
Measured: Day 0, Day 60
Total Cholesterol serum concentration (mg/dL)
Changes in total cholesterol concentration. A concentration less than 200 mg/dL is recommended, with a normal upper limit between 200 and 239 mg/dL. Measurements above 240 mg/dL indicate excessive consumption through diet or familial hypercholesterolemia
Measured: Day 0, Day 60
Triglycerides serum concentration (mg/dL)
Changes in triglyceride concentration. Normal values are less than 150 mg/dL; the upper limit is between 150 and 199 mg/dL. However, values between 200 and 499 mg/dl are considered high or very high (above 500 mg/dl).
Measured: Day 0, Day 60
LDL-cholesterol serum concentration (mg/dL)
Changes in LDL-cholesterol concentration. Optimal levels are less than 100 mg/dL, although concentrations between 100 and 129 mg/dL are considered almost optimal. The upper limit of normal is between 130 and 159. Values between 160 and 189 mg/dL are considered high, and those above 190 mg/dL as very high.
Measured: Day 0, Day 60
HDL-cholesterol serum concentration (mg/dL)
Changes in HDL-cholesterol concentration. Values above 60 mg/d Lare considered a protective factor against cardiovascular diseases.Concentrations between 40 and 59 mg/dL are correct, while values below 40 mg/dL are one of the main risk factors for cardiovascular disease.
Measured: Day 0, Day 60
Creatinine serum concentration (mg/dL)
Changes in creatinine concentration. Normal values are 0.7 to 1.3 mg/dL (61.9 to 114.9 µmol/L) for men and 0.6 to 1.1 mg/dL (53 to 97.2 µmol/L) for women. Women often have lower creatinine levels than men, due to less muscle mass.
Measured: Day 0, Day 60
Urate serum concentration (mg/dL)
Changes in urate concentration. Normal values are between 3.5 and 7.2 milligrams per deciliter (mg/dL).
Measured: Day 0, Day 60
Adherence to the Mediterranean Diet
Questionnaire on Consumption Adherence to the Mediterranean Diet. The questionnaire consists of 14 questions with a variable score on different aspects of the diet and the Mediterranean pattern. A score less than 9 indicates poor adherence, while a score of 9 or more points indicates good adherence.
Measured: Day 0, Day 60
24 hour food record questionnaire
Questionnaire to find out the nutritional and dietary habits of each participant. The volunteer will write down all the food and drinks ingested over 1 day (24 hours). The answers will allow calculating the total amount of food consumed and calories ingested. In addition, the data will be evaluated quantitatively and qualitatively, classifying the diet in terms of diversity and balance following the recommendations of the Spanish Society of Community Nutrition (SENC 2016).
Measured: Day 0, Day 60
International Physical Activity Questionnaire (IPAQ)
The questionnaire is divided into 4 categories of questions depending on the type of activity for which information is requested (vigorous, moderate, walking, sedentary). The quantitative results allow calculating the TOTAL Energy Metabolism Rate (MET) x minute/week for each subject. Qualitative results categorize the volunteers' physical activity into low activity (1), moderate activity (2), or vigorous activity (3).
Measured: Day 0, Day 60
Questionnaire on quality of life (EuroQoL 5D)
The EuroQol 5D quality of life questionnaire will be used. The questionnaire is divided into two parts. In the first, questions are asked regarding mobility, personal care, daily activities and the presence of pain, discomfort, anxiety or depression. In the second part, the patient must use a visual analog health scale from 1 to 10 to indicate their subjective state of health, with 0 being the worst state of health imaginable and 10 being the best state of health imaginable.
Measured: Day 0, Day 60
Gastrointestinal symptoms rating scale (GSRS)
The GSRS is a specific instrument for the assessment of digestive symptoms that includes 15 items grouped into 5 blocks based on the different gastrointestinal symptoms. The 5 groups of symptoms represent reflux, abdominal pain, indigestion, diarrhea and constipation. It has a score based on a Likert-type scale of 7 degrees, where 1 represents the most positive option and 7 the most negative.
Measured: Day 0, Day 60
Sensory perception
The taste and olfactory sensory perception of the participants for the products will be evaluated by means of a questionnaire using Visual Analogue Scales (VAS) with a score of 0 to 10.
Measured: Day 0, Day 60
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted4 Aug 2022
- Study start1 Jul 2022
- Primary completion31 Dec 2022 (estimated)
- Study completion1 Jul 2023 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for DiabetesStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Prospective
- Enrolment
- 24 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Instituto de Investigación Hospital Universitario La Paz
- Sponsor type
- University, hospital or other
- Collaborators
- Fundació Eurecat, Laboratoires Grand Fontaine S.L
- Responsible party
- Sponsor
- Investigators
- Samara Palma-Milla, MD, PhD, Principal investigator, Hospital La Paz
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05488210
- Sponsor's protocol ID
- PI-6092
- Acronym
- DIABEST
- Status last verified
- Apr 2022
- First submitted
- 2 Aug 2022
- Last updated
- 4 Aug 2022
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 4 Aug 2022. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Study to Evaluate the Effect of Consuming an Oral Nutritional Supplement (ONS) Specifically for Diabetic Patients on Adherence and Gastrointestinal Tolerance and Nutritional Status in Patients With DM2 and Malnutrition
- ClinicalTrials.gov ID
- NCT05488210
- Acronym / sponsor ID
- DIABEST / PI-6092
- Conditions
- Diabetes, Malnutrition
- Keywords
- DM2, Oral nutritional supplement, Malnourished
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 24 participants (estimated)
- Lead sponsor
- Instituto de Investigación Hospital Universitario La PazUniversity, hospital or other
- Collaborators
- Fundació Eurecat, Laboratoires Grand Fontaine S.L
- Study start
- 1 Jul 2022 (actual)
- Primary completion
- 31 Dec 2022 (estimated)
- Study completion
- 1 Jul 2023 (estimated)
- First posted
- 4 Aug 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Diabetes Mellitus (DM) is one of the most prevalent chronic diseases today, it is reaching epidemic proportions, mainly caused by the increase in type 2 diabetes (DM2).The foundation of any hypoglycemic treatment is based on a healthy diet, daily physical exercise and adequate health education with the collaboration of the patient. Diet is sometimes the only necessary therapy since approximately 80% of patients with DM2 are usually overweight, what is mainly wanted with diet is to achieve normal blood glucose levels both fasting and in the postprandial phase. This diet must be a varied diet combining foods from the different food groups; however, carbohydrate control must be one of the key strategies for glycemic control. Currently, there is also talk of the concept of disease-related malnutrition (DRM). DRM is malnutrition associated with a pathological state, with the presence of inflammation being a key factor in determining its etiology. This inflammation can be chronic or acute depending on the type of pathology. Therefore, the fiber and carbohydrate composition of oral nutritional supplements are important for glycemic control, so a study is proposed to evaluate the effect of consuming a ONS hypercaloric/high-protein (HC/HP) with fiber, and enriched in calcium, Vitamin D and DHA on adherence and tolerance of the product and nutritional status in patients with DM2 and malnutrition.
Detailed description
Longitudinal, prospective exploratory study, to evaluate the effect of consuming an oral nutritional supplement (ONS) HC/HP with fiber, and enriched in calcium, Vitamin D and Docosahexaenoic acid (DHA) on adherence and tolerance of the product and nutritional status in patients with DM2 and malnutrition, in a period of 60 days. Twenty-four volunteers will be recruited at the La Paz University Hospital of Madrid. Participants should meet the next inclusion criteria: men and woman enter 18 and 85, with DM2 previously diagnosed and controlled, with malnutrition diagnosed according to the Global Leadership Initiative on Malnutrition (GLIM) criteria, who require taking ONS, willing to consume the ONS during the study and adequate cultural level and understanding of the clinical study. Follow up will include 4 individualized visits.
Study design
- Observational model
- Other
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Malnourished DM2 patients | – | Dietary Supplement: FontActiv DiaBest HP/HCDiabetic patients who present malnutrition through the GLIM criteria |
Who may qualify
- Ages
- 18 to 85 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- Diabetic patients who present malnutrition through the GLIM criteria
Key inclusion criteria (7 listed)
- Men and women enter 18 and 85 years old.
- Patients with DM2 previously diagnosed and controlled.
- Patients with malnutrition diagnosed according to GLIM criteria.
- Patients who require taking ONS.
- Patients willing to consume the ONS during the study period.
Key exclusion criteria (10 listed)
- Subjects with enteral or parenteral nutrition.
- Subjects with poorly controlled DM2.
- Subjects with dementia, eating behavior disorders, history of serious neurological or psychiatric pathology that may interfere with adherence to the consumption of the ONS.
- Subjects suffering from alcoholism or substance abuse that may interfere with adherence to the consumption of the ONS.
- Subjects with a diagnosis of kidney or liver disease under pharmacological treatment.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| FontActiv DiaBest HP/HCAlso: ExperimentalDaily intake of two FontActiv DiaBest HP/HC during 2 months | Dietary supplement | Malnourished DM2 patients |
Primary outcome
Weight gain (kg)
Time frame: Day 0, Day 60
Changes in body weight. It is measured using a digital scale for clinical use (capacity 0-150 kg),with the person positioned with their back to the viewer, without shoes, wearing a minimum of warm clothing (pants and t-shirt), heels together, looking forward and posture straight body.
Fat mass (%)
Time frame: Day 0, Day 60
Changes in the percentage (%) of Fat Mass via bioelectrical impedance
Muscle mass (%)
Time frame: Day 0, Day 60
Changes in the percentage (%) of Muscle Mass via bioelectrical impedance
24 secondary outcomes
Waist circumference (cm)
Time frame: Day 0, Day 60
Body Mass Index (kg/m2)
Time frame: Day 0, Day 60
Extracellular water (%)
Time frame: Day 0, Day 60
Intracellular water (%)
Time frame: Day 0, Day 60
Total Body Water (%)
Time frame: Day 0, Day 60
Phase angle (º)
Time frame: Day 0, Day 60
Body Cell Mass (%)
Time frame: Day 0, Day 60
Albumin serum concentration (g/dL)
Time frame: Day 0, Day 60
Prealbumin serum concentration (mg/dL)
Time frame: Day 0, Day 60
Glucose serum concentration (mg/dL)
Time frame: Day 0, Day 60
Insulin serum concentration (IU/mL)
Time frame: Day 0, Day 60
HbA1c serum concentration (%)
Time frame: Day 0, Day 60
Total Cholesterol serum concentration (mg/dL)
Time frame: Day 0, Day 60
Triglycerides serum concentration (mg/dL)
Time frame: Day 0, Day 60
LDL-cholesterol serum concentration (mg/dL)
Time frame: Day 0, Day 60
HDL-cholesterol serum concentration (mg/dL)
Time frame: Day 0, Day 60
Creatinine serum concentration (mg/dL)
Time frame: Day 0, Day 60
Urate serum concentration (mg/dL)
Time frame: Day 0, Day 60
Adherence to the Mediterranean Diet
Time frame: Day 0, Day 60
24 hour food record questionnaire
Time frame: Day 0, Day 60
International Physical Activity Questionnaire (IPAQ)
Time frame: Day 0, Day 60
Questionnaire on quality of life (EuroQoL 5D)
Time frame: Day 0, Day 60
Gastrointestinal symptoms rating scale (GSRS)
Time frame: Day 0, Day 60
Sensory perception
Time frame: Day 0, Day 60
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 4 Aug 2022.
- Individual participant dataSharing planned: No
Related trials for Diabetes
Not yet recruitingPhase 3
Efficacy and Safety of Once-Weekly SHR-3167 Compared With Once-Daily Insulin Glargine in Adults With Insulin-Naive Type 2 Diabetes
Type 2 Diabetes
Active, not recruiting
Digital Reinforcement of Motivational Interviewing Micro-Skills Among Primary Care Healthcare Professionals
Hypertension (Without Type 2 Diabetes Mellitus)
Recruiting
Effects of Lean Pork Loin Intake on Protein Homeostasis and Glucose Regulation in Prediabetic Adults
Hyperglycaemia (Non Diabetic), Prediabetes
Recruiting
PAW-Hydrogel for Chronic Wound Healing
Diabetic Foot Ulcer (DFU), Pressure Ulcer (PU)
Recruiting
Investigating Vascular Properties of HEMI and SPG Signals in Individuals With or at Risk for Chronic Kidney Disease
Chronic Kidney Disease, Hypertension (HTN)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Samara Palma-Milla, MD, PhD principal investigator
Hospital La Paz
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Diabetes and Malnutrition, run by Instituto de Investigación Hospital Universitario La Paz at 1 site in Spain.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 4 Aug 2022. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Spain. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Bricia López-Plaza, PhD (917277000 ext. 442507, bricia.plaza@idipaz.es), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Weight gain (kg) (time frame: Day 0, Day 60). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Aug 2022.